NGM · Medical - Devices

TELA Bio, Inc. (TELA) Stock

$0.71 +2.24% NGM: TELA Healthcare

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Valuation

MetricValue
Price$0.71
Market Cap$31.63M
P/E Ratio-0.87
P/B Ratio-7.61
P/S Ratio0.38
EPS (TTM)$-0.83
52-Week High$2.14
52-Week Low$0.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-650.00%
ROA-57.00%
ROCE-64.94%
Gross Margin-42.50%
Operating Margin-42.50%
Net Margin-49.30%
Debt/Equity-10.84
Current Ratio4.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$29.0M$41.0M$58.0M$69.0M$80.0M
Operating Profit$-29.0M$-39.0M$-44.0M$-34.0M$-34.0M
Net Profit$-33.0M$-44.0M$-47.0M$-38.0M$-39.0M
EPS$-2.30$-2.73$-2.04$-1.33$-0.83
Op Margin-100.0%-94.2%-75.4%-49.2%-42.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$63.0M$68.0M$78.0M$87.0M$81.0M
Total Liabilities$42.0M$54.0M$59.0M$59.0M$75.0M
Cash$44.0M$42.0M$47.0M$53.0M$51.0M
Borrowings$31.0M$41.0M$43.0M$43.0M$56.0M

Latest News

TELA Bio to Announce Second Quarter 2026 Financial Results GlobeNewswire · Jul 20, 2026 Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25 Simply Wall St. · May 15, 2026 TELA Bio, Inc. Q1 2026 Earnings Call Summary Moby · May 13, 2026 TELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ... GuruFocus.com · May 13, 2026 TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates Zacks · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-30.0M$-41.0M$-41.0M$-42.0M$-28.0M
Investing Cash Flow$-1.0M$-4.0M$-1.0M$3.0M$0
Financing Cash Flow$0$-4.0M$0$0$0
Net Cash Flow$-30.0M$-2.0M$5.0M$6.0M$-2.0M
Free Cash Flow$-31.0M$-43.0M$-41.0M$-43.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-1.41
FCF Yield-91.69%
Quick Ratio3.61
Interest Coverage-6.80
Return 1Y-61.11%
Return 3Y-92.18%
Return 5Y-94.66%

Ownership

Insiders Held7.71%
Institutions Held68.96%
Institutions Float Held74.72%
Institutional HolderSharesReport Date
Essex Woodlands Management Inc.7,714,7092026-03-31
Nantahala Capital Management, LLC5,144,1142026-03-31
Stonepine Capital Management, LLC2,617,2522026-03-31
SilverArc Capital Management, LLC2,259,3122026-03-31
Vanguard Capital Management LLC1,540,6242026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio, Inc. is led by CEO Antony Koblish, employs 209 people, headquartered in US, publicly traded since 2019.

TELA Bio, Inc. (TELA) stock trades at $0.71 with a market capitalization of $31.63M. The stock is valued at a price-to-earnings (P/E) ratio of -0.87, price-to-book of -7.61, price-to-sales of 0.38. Over the past 52 weeks the stock has ranged between $0.50 and $2.14, and currently trades 66.8% below its 52-week high.

On profitability, TELA Bio, Inc. generates a return on equity (ROE) of -650.00%, return on capital employed of -64.94%, an operating margin of -42.50%, a net profit margin of -49.30%.

Official website: www.telabio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides